MedTrace Logo

Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma

NCT01752205 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2012-12-19

No results posted yet for this study

Summary

The purpose of this study is to test the safety and effectiveness of erlotinib and chemoradiotherapy in patients with unresectable esophageal or gastro-esophageal squamous cancer .

Conditions

  • Esophageal Squamous Carcinoma

Interventions

DRUG

Paclitaxel

45mg/m2/w,total 6 weeks

DRUG

Erlotinib

150mg/d,days 1-42,total 6 weeks

RADIATION

Radiation therapy

Sponsors & Collaborators

  • The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

    lead OTHER

Principal Investigators

  • Xu jianming, M.D. · The Affiliated Hospital of the Chinese Academy of Military Medical Science

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-05-31
Completion
2014-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01752205 on ClinicalTrials.gov